Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALOP2 in locally advanced pancreatic cancer
ISRCTN50083238Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of nelfinavir, capecitabine, gemcitabine and paclitaxel in pancreatic cancer (PC) (4 arms), sponsored by University of Oxford. Primary endpoints: Maximum tolerated dose and safety, Progression-free survival and 1 more. Started Mar 2016; status: completed.
02
Drugs
nelfinavircapecitabinegemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ISRCTN50083238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50083238.